

# Clinical trials of poly ADP-ribose polymerase (PARP) inhibitor for ovarian cancer in all type of patient (BRCA mutated or not)

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 PARP inhibitors

| Trial   | Treatments  | Patients   | Trials design and methods  |
|---|---|--|----------------------------|
| <b>Rucaparib vs</b>   |   |  |                            |
| <b>ARIEL 4</b> <i>ongoing</i><br>[NCT02855944]<br>n=NA              | -   | -  |                            |
| <b>ARIEL 3</b> <i>ongoing</i><br>[Rucaparib]<br>n=NA<br>follow-up:  | -   | maintenance treatment  |                            |
| <b>niraparib vs placebo</b>   |   |  |                            |
| <b>ENGOT-OV16/NOVA</b><br>[ NCT01847274]<br>n=138/65<br>follow-up:  | niraparib (300 mg) once daily<br>versus<br>placebo                      | patients with platinum-sensitive, recurrent ovarian cancer   | double-blind               |
| <b>olaparib vs placebo</b>  |   |  |                            |
| <b>SOLO2/ENGOT-Ov21</b><br>[ NCT01874353]<br>n=196/99<br>follow-up: | olaparib 300 mg in two 150 mg tablets, twice daily<br>versus<br>placebo | patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation   | double-blind international |
| <b>olaparid vs placebo</b>  |   |  |                            |
| <b>Ledermann , 2012</b><br>[ NCT00753545]<br>n=NA<br>follow-up:     | olaparib, at a dose of 400 mg twice daily<br>versus<br>placebo          | patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen |                            |

## References

**ARIEL 4** , :

**ARIEL 3** , :

**ENGOT-OV16/NOVA** , :

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Drum A, Tinker AV, du Bois A, Gonzalez-Martn A, Follana P, Benigno B, Rosenberg P, Gilb Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375:2154-2164 [27717299]

**SOLO2/ENGOT-Ov21** , :

Pujade-Lauraine E, Ledermann JA, Selle F, GebSKI V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017;: [28754483]

**Ledermann, 2012:**

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012;366:1382-92 [22452356]

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.